发明名称 Method for the administration of anti-cancer drugs
摘要 An administration method comprising: determining a cancer type through (i) first data indicating that an Estrogen Receptor (ER) is negative and a Human Epidermal growth factor Receptor-2 (Her2) is negative, or (ii) second data indicating that at least one of the ER and the Her2 is positive; and when the cancer type is determined through (i) the first data indicating that the ER is negative and the Her2 is negative: first performing a docetaxel administration cycle comprising administrating docetaxel to a patient multiple times at certain intervals; and then performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals, and when the cancer type is determined through (ii) the second data indicating that at least one of the ER and Her2 is positive: first performing the FEC administration cycle; and then performing the docetaxel administration cycle.
申请公布号 US8865663(B2) 申请公布日期 2014.10.21
申请号 US200912934146 申请日期 2009.01.26
申请人 Japan Breast Cancer Research Group 发明人 Toi Masakazu;Iwata Hiroji;Kuroi Katsumasa;Nakamura Seigo;Ohno Shinji;Masuda Norikazu;Aogi Kenjiro;Sato Nobuaki;Akiyama Futoshi;Kurosumi Masafumi;Tsuda Hitoshi
分类号 A61K31/704;G06Q50/00;A61P35/00;A61K31/337;C07K14/71;C07K14/72;A61K31/513;A61K31/675;G06F19/00;G06Q50/22 主分类号 A61K31/704
代理机构 Wenderoth, Lind & Ponack, L.L.P 代理人 Wenderoth, Lind & Ponack, L.L.P
主权项 1. A method of treating cancer which is negative for expression of both an Estrogen Receptor (ER) and a Human Epidermal Growth Factor Receptor-2 (HER-2), comprising: first determining that the cancer is negative for expression of ER, and negative for expression of HER2; second performing a docetaxel administration cycle consisting of administrating docetaxel to a patient multiple times at certain intervals; and then third performing a 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) administration cycle comprising administrating 5-fluorouracil, epirubicin, and cyclophosphamide to the patient multiple times at certain intervals.
地址 Tokyo JP